Business
BeyondSpring Reports First-Quarter 2026 Financial Results and Provides Corporate Update
AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability SEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy FLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other di
About this update from Beyondspring, Inc.
[{"type":"image","alt":"BeyondSpring, Inc.","displaySize":"","headline":null,"caption":"BeyondSpring, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":255,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/06b3b5b1556b23b23891f3b41c446766"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/iztnDk_H5MGcKZO6_GJ5Qg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/06b3b5b1556b23b23891f3b41c446766","width":255,"height":89},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/iztnDk_H5MGcKZO6_GJ5Qg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NztjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/06b3b5b1556b23b23891f3b41c446766","width":255,"height":89}},"lazy":false},{"type":"text","content":"AACR 2026 Data Positions Plinabulin as a Potential Backbone Agent to Combine with Antibody-Drug Conjugate (ADC)-Based Therapies to Improve Anti-Cancer Efficacy and Tolerability","length":176,"tagName":"p"},{"type":"text","content":"SEED Advances First Molecular Glue Degrader into Clinical Development with Biomarker-Driven Strategy","length":100,"tagName":"p"},{"type":"text","content":"FLORHAM PARK, N.J., May 13, 2026 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage company developing transformative therapies for the treatment of cancer and other diseases, today announced its financial results for the quarter ended March 31, 2026, and provided a corporate update highlighting significant scientific and clinical advancements across its pipeline.","length":420,"tagName":"p"},{"type":"text","content":"“Plinabulin continues to demonstrate the ability to enhance both efficacy and tolerability in ADC-based regimens, supporting its positioning as a potential backbone agent across a rapidly evolving treatment landscape,” said Dr. Lan Huang, Co-Founder, Chair, and Chief Executive Officer of BeyondSpring. “Data presented at AACR 2026 further highlights the expanding value of our pipeline and reinforces our strategy of advancing highly differentiated therapies with the potential to address significant unmet medical needs. We believe Plinabulin has the potential to become a foundational combination agent that unlocks the full clinical and commercial value of ADC therapies.”","length":676,"tagName":"p"},{"type":"text","content":"Dr. Huang contin...